Robert W. Baird initiated coverage on VistaGen with a new price target
$VTGN
Biotechnology: Pharmaceutical Preparations
Health Care
Robert W. Baird initiated coverage of VistaGen with a rating of Outperform and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | $0.90 | Buy → Hold | Jefferies |
| 12/17/2025 | Buy → Hold | Maxim Group | |
| 12/17/2025 | Outperform → Mkt Perform | William Blair | |
| 12/17/2025 | $1.00 | Buy → Hold | Stifel |
| 12/7/2023 | $15.00 | Hold → Buy | Jefferies |
| 8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
| 7/22/2022 | Outperform → Neutral | Robert W. Baird | |
| 7/22/2022 | Buy → Hold | Jefferies |
Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability data were consistent with previous clinical trials Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscien
Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial Received FDA "Study May Proceed" letter under refisolone Investigational New Drug (IND) application to support further clinical development in the U.S. for treatment of moderate to severe vasomotor symptoms (hot flashes) due to
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening conditions1. As of May 31, 2026, the Company estimates
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90
Maxim Group downgraded VistaGen from Buy to Hold
William Blair downgraded VistaGen from Outperform to Mkt Perform
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
10-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability data were consistent with previous clinical trials Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscien
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at